We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boehringer, Teva Facing Another Aggrenox Pay-for-Delay Lawsuit
Boehringer, Teva Facing Another Aggrenox Pay-for-Delay Lawsuit
Boehringer Ingelheim and Teva were again accused of blocking generic competition to the brandmaker’s antistroke drug Aggrenox just days after their bid to toss a similar lawsuit was denied.